CytoDyn Inc., a clinical-stage oncology company, announced it will present two research posters at the AACR Annual Meeting 2026 in San Diego. The presentations focus on leronlimab, a monoclonal antibody targeting the CCR5 receptor, showing promising results in metastatic triple-negative breast cancer and colorectal cancer. These studies explore leronlimab's role in enhancing immune response and improving survival, supporting CytoDyn's strategy to develop new cancer therapies. Presentation details will be available on CytoDyn's website after the event.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
